FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2128480323> ?p ?o ?g. }

• W2128480323 endingPage "15329" @default.
• W2128480323 startingPage "15326" @default.
• W2128480323 abstract "The gene SURF1 encodes a factor involved in the biogenesis of cytochrome c oxidase, the last complex in the respiratory chain. Mutations of theSURF1 gene result in Leigh syndrome and severe cytochromec oxidase deficiency. Analysis of seven unrelated patients with cytochrome c oxidase deficiency and typical Leigh syndrome revealed different SURF1 mutations in four of them. Only these four cases had associated demyelinating neuropathy. Three mutations were novel splicing-site mutations that lead to the excision of exon 6. Two different novel heterozygous mutations were found at the same guanine residue at the donor splice site of intron 6; one was a deletion, whereas the other was a transition [588+1G>A]. The third novel splicing-site mutation was a homozygous [516–2_516–1delAG] in intron 5. One patient only had a homozygous polymorphism in the middle of the intron 8 [835+25C>T]. Western blot analysis showed that Surf1 protein was absent in all four patients harboring mutations. Our studies confirm that theSURF1 gene is an important nuclear gene involved in the cytochrome c oxidase deficiency. We also show that Surf1 protein is not implicated in the assembly of other respiratory chain complexes or the pyruvate dehydrogenase complex. The gene SURF1 encodes a factor involved in the biogenesis of cytochrome c oxidase, the last complex in the respiratory chain. Mutations of theSURF1 gene result in Leigh syndrome and severe cytochromec oxidase deficiency. Analysis of seven unrelated patients with cytochrome c oxidase deficiency and typical Leigh syndrome revealed different SURF1 mutations in four of them. Only these four cases had associated demyelinating neuropathy. Three mutations were novel splicing-site mutations that lead to the excision of exon 6. Two different novel heterozygous mutations were found at the same guanine residue at the donor splice site of intron 6; one was a deletion, whereas the other was a transition [588+1G>A]. The third novel splicing-site mutation was a homozygous [516–2_516–1delAG] in intron 5. One patient only had a homozygous polymorphism in the middle of the intron 8 [835+25C>T]. Western blot analysis showed that Surf1 protein was absent in all four patients harboring mutations. Our studies confirm that theSURF1 gene is an important nuclear gene involved in the cytochrome c oxidase deficiency. We also show that Surf1 protein is not implicated in the assembly of other respiratory chain complexes or the pyruvate dehydrogenase complex. Leigh syndrome cytochrome c oxidase Leigh syndrome associated with highly reduced COX activity magnetic resonance imaging pyruvate dehydrogenase pyruvate dehydrogenase complex reverse transcriptase polymerase chain reaction base pair Leigh syndrome (LS),1 or subacute necrotizing encephalomyelopathy (MIM 256000), is a progressive and often fatal neurological disorder in young children, characterized by bilaterally symmetrical necrotic lesions in the brain stem and basal ganglia (1Leigh D. J. Neurol. Neurosurg. Psychiatry. 1951; 14: 216-221Crossref PubMed Scopus (616) Google Scholar). A common associated biological feature is hyperlactatemia. It is a genetically heterogeneous disease, caused by defects in the enzymes normally involved in the respiratory chain and in mitochondrial energetic metabolism (e.g. pyruvate dehydrogenase). One of the most common enzymatic defects is the deficiency of cytochrome c oxidase (COX), complex IV of the mitochondrial respiratory chain. Recently, mutations in the nuclearSURF1 gene, which encodes a factor involved in COX biogenesis, have been identified in patients with LS (2Zhu Z. Yao J. Johns T. Fu K. De Bie I. Macmillan C. Cuthbert A.P. Newbold R.F. Wang J. Chevrette M. Brown G.K. Brown R.M. Shoubridge E.A. Nat. Genet. 1998; 20: 337-343Crossref PubMed Scopus (531) Google Scholar, 3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar). This gene is located on chromosome 9q34, consists of nine exons, and encodes a protein of 300 amino acids. We have studied 58 patients who were thought to have LS based on their clinical features and on magnetic resonance imaging (MRI), which showed lesions on the basal ganglia and the brain stem. 15 of these patients presented cytochromec oxidase deficiency, seven were typical LS, but only four had a severe COX deficiency (LScox). 15 other patients were defective in pyruvate dehydrogenase with mutations in the E1 α-PDH and Hs-PDX1 genes, 11 were found to have a complex I deficiency, and four had the clinical features of the maternal inheritance Leigh syndrome with a neuropathy ataxia retinitis pigmentosa mutation in the ATPase6 gene of the mitochondrial DNA. We identified six mutations, including three new splicing-site mutations, in the SURF1 gene in the four patients with typical LS and severe COX deficiency. Patient 1 was the first child of non-consanguineous parents. At nine months, she presented delayed growth, difficulties in swallowing, severe hypotonia, trunk ataxia, nystagmus. She had optic atrophy and a demyelinating peripheral neuropathy. Brain MRI showed symmetric lesions of the basal ganglia and brain stem. She had hyperlactatemia (4.9 mmol/liter; normal value is below 2 mmol/liter). She died at 4 years. Patient 2 was born to non-consanguineous parents. She developed a mild psychomotor delay with progressive ataxia, ophthalmoplegia and retinopathy, and a demyelinating neuropathy. Recurrent vomiting attacks are associated with increasing ptosis and ataxia. At 2 years, brain MRI showed lesions in the brain stem and thalamus and cerebellar atrophy. High levels of lactate were found in blood (4.14 mmol/liter). She is still alive at 14 years of age. Patient 3 was the third child of non-consanguineous parents. The mother had two miscarriages. A sister died at 2 months of age with the diagnosis of sudden death. At 1 year of age the patient had a severe growth delay, a trunk ataxia, pyramidal signs, dystonia, and abnormal ocular movements. She had difficulties in swallowing and presented recurrent respiratory distress. She had optic atrophy, demyelinating neuropathy, and hyperlactatemia (4.75 mmol/liter). MRI showed bilateral, symmetrical lesions of the basal ganglia and the brain stem. She died at the age of 2 years. Patient 4 was born to consanguineous parents and had a cousin affected by the same condition. She had a metabolic encephalopathy, which was revealed at 3 months of age by severe hypotonia, hyperlactatemia, and nystagmus. The MRI exhibited bilateral lesions in the caudate nuclei. Patient 5 was a Lybian Arab male baby born from first cousin parents. Persistent vomiting, profound developmental delay, and severe hypotonia were the main clinical features leading to his death at 18 months. The MRI showed lesions typical of LS. Patient 6 was the only child of consanguineous parents (common grandmother). Growth retardation and hypotonia were observed at 4 months. At the age of 6 years he presented a progressive encephalomyelopathy, with cortical atrophy and necrosis of the basal ganglia and brain stem. The lactate level in the blood was 3.2 mm and 5.4 mm in the cerebrospinal fluid. Patient 7, a girl, was born to consanguineous parents (first cousin parents) and had a brother affected by the same disorder (developmental delay and hyperlactatemia). Both showed typical Leigh syndrome features confirmed by cerebral tomography scan examination. MRI detected lesions in the basal ganglia. They are still alive at the age of 10 and 7 years, respectively. Enzymatic assays were carried out on mitochondria isolated from muscle or lymphoblasts (4Trounce I.A. Kim Y.L. Jun A.S. Wallace D.C. Methods Enzymol. 1996; 264: 484-509Crossref PubMed Google Scholar) of all patients except patient 5, for whom assays were performed in muscle homogenate. The activities of the respiratory chain complexes were measured spectrophotometrically as described previously (5Degoul F. Nelson I. Lestienne P. Francois D. Romero N. Duboc D. Eymard B. Fardeau M. Ponsot G. Paturneau-Jouas M. Chaussain M. Leroux J.P. Marsac C. J. Neurol. Sci. 1991; 101: 168-177Abstract Full Text PDF PubMed Scopus (43) Google Scholar). Pyruvate dehydrogenase complex (PDHC) activity was measured in lymphoblastoid cell lines by the release of [14C]CO2 from [1-14C]pyruvic acid (6Bonne G. Benelli C. De Meirleir L. Lissens W. Chaussain M. Diry M. Clot J.P. Ponsot G. Geoffroy V., M. Leroux J.P. Marsac C. Pediatr. Res. 1993; 33: 284-288Crossref PubMed Scopus (33) Google Scholar). For Western blot analysis, proteins derived from lymphoblastoid cell lines (patients 1, 2, 3, 4, and 7) or fibroblasts (patient 5) were separated by 10% SDS polyacrylamide gel electrophoresis under reducing conditions and transferred onto nitrocellulose membrane (7Geoffroy V. Poggi F. Saudubray J.M. Fouque F. Lissens W. Lindsay G. Sanderson S.J. De Merleir L. Marsac C. Benelli C. Pediatrics. 1996; 97: 267-272PubMed Google Scholar). The blots were probed with polyclonal antibodies directed against the PDH holoenzyme or against the C terminus of the Surf1 protein (peptide-Y-13-V) (3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar). Genomic DNA was purified by use of the DNAzol Reagent (Life Technologies, Inc.) as described by the manufacturer. The nine exons of the SURF1gene were amplified as described by Tiranti et al. (3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar) and sequenced in a commercially available, automated sequencer (Genome Express, Grenoble, France). Total RNA was extracted from cultured lymphoblasts with an RNA-plusTM kit (Quantum Bioprobe, Quebec, Canada). Each RNA sample (5 μg) was reverse-transcribed using d(T)18 primers and a first-strand cDNA synthesis kit (Amersham Pharmacia Biotech) according to the manufacturer's instructions. The coding sequence from exon 4 to exon 9 was amplified by PCR as described by Poyau et al. (8Poyau A. Buchet A. Bouzidi M.F. Zabot M.T. Echenne B. Yao J. Shoubridge E.A. Godinot C. Hum. Genet. 2000; 106: 194-205Crossref PubMed Scopus (58) Google Scholar). We also used three new primer pairs; the first pair was chosen to study patient 3. For161 (5′-CAAAAGCGGAAGATGACTCC-3′) and Rev558 (5′-GGTTCGTTCCCAGGAAGAAA-3′) amplified the cDNA region from base 181 to base 538. For RT-PCR of patient 5, a first PCR was done using the primers For-9 (5′-CCGGGTGCGATGGCGGCGGTGGCTGCGTTGCAG-3′) and Rev955 (5′-CAGTAGCACATGATCCAGCATAAAG-3′). A “nested” PCR was then carried out on this first product with For435 (5′-GGCCCGGGAGGGCGGCCTC-3′) and Rev927 (5′-CAGTCTTGAAATACTGCATTATCCAGGG-3′). The PCR products were analyzed by agarose gel electrophoresis (2%), stained with ethidium bromide (0.5 μg/ml), and visualized by UV transillumination. cDNA fragments containing putative deletions in the gene were purified from PCR products by use of a Qiaquick PCR extraction kit (Qiagen, Courtaboeuf, France) and sequenced as above. We studied seven unrelated patients with typical LS. Four of them (patients 1, 2, 3, and 5) had dramatically reduced COX activity. This decrease was obvious in mitochondria purified from fresh muscle biopsy (Table I) and lymphoblastoid cell lines (Table II). Patients 4, 6, and 7 presented only a slight decrease of COX activity in muscle (Table I).Table ICOX activity in muscle mitochondria (from controls and patients 1, 2, 3, and 4) and muscle homogenate (controls and patient 5), expressed in milliUnits/mg of protein and in COX/citrate synthase ratiomilliunits/mg of proteinCOX/citrate synthase ratioMuscle mitochondriaControl values (N = 24)3151 ± 7601.3 ± 0.3Patient 1880 – 8250.2Patient 21335 – 14400.28Patient 3764 – 6890.17Patient 417600.68Patient 61505 – 15770.50Patient 71461 – 14550.60Muscle homogenateControl range80 – 1800.85 – 1Patient 5150.10 Open table in a new tab Table IICOX activity of mitochondria purified from lymphoblastoid cell lines (control, 1, 2, and 3)COX (milliunits/mg of protein)CII (milliunits/mg of protein)COX/CSaseCII/CSasePDH (milliunits/mg of protein)Control252840.450.15552Patient 1601990.070.21543Patient 21201870.140.21856Patient 3561280.060.15641 Open table in a new tab No band corresponding to the Surf1 protein was found by Western blot analysis of the four typically LScox patients 1, 2, 3, and 5 (Fig. 1). Conversely, a Surf1-specific band was detected in patients 4 and 7. The intensity of the band was similar to that found in the controls. A nonspecific band just below the Surf1 protein was equally intense in all samples, suggesting that the quantity of total proteins was approximately the same. These results prompted us to look for mutations in the SURF1gene by directly sequencing PCR fragments obtained with primers described previously (3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar). Six different mutations were found in the four patients who lacked the Surf1 protein (patients 1, 2, 3, and 5) (Fig. 2). Three of these mutations have already been described. The most frequent mutation reported inSURF1 gene, the [312_321del311_312insAT], was found in patients 1 and 2 (2Zhu Z. Yao J. Johns T. Fu K. De Bie I. Macmillan C. Cuthbert A.P. Newbold R.F. Wang J. Chevrette M. Brown G.K. Brown R.M. Shoubridge E.A. Nat. Genet. 1998; 20: 337-343Crossref PubMed Scopus (531) Google Scholar, 3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar); the [737T>C] mutation was detected in patient 2 (8Poyau A. Buchet A. Bouzidi M.F. Zabot M.T. Echenne B. Yao J. Shoubridge E.A. Godinot C. Hum. Genet. 2000; 106: 194-205Crossref PubMed Scopus (58) Google Scholar), and a mutation in the splicing donor site of intron 3 [240+1G>T] was found in patient 3 (9Tiranti V. Jaksch M. Hofmann S. Galimberti C. Hoertnagel K. Lulli L. Freisinger P. Bindoff L. Gerbitz K.D. Comi G.P. Uziel G. Zeviani M. Meitinger T. Ann. Neurol. 1999; 46: 161-166Crossref PubMed Scopus (110) Google Scholar). Three new mutations were found, two of which involved the first base of intron 6: a deletion of the G in position 588+1 was detected in patient 1, and a transition [588+1G>A] was found in patient 3. Patient 5 harbored an AG deletion in the acceptor site of intron 5, [516–2_516–1delAG]. Patients 1, 2, and 3 were compound heterozygotes, whereas patient 5 was homozygous for the mutation. We carried out RT-PCR to study the consequences of these mutations on the RNA sequence on patients 1, 2, 3, and 5 (Fig.3 A). A single band of 730 bp was obtained in samples from patient 2 and a control. However, using the same primers we obtained two bands from the samples of patients 1 and 3. The additional band was ∼60 bp smaller than the control band in both cases (660 bp). The sequencing of these RT-PCR products of patients 1 and 3 permitted us to conclude that the two mutations in the first base of the donor splice site of intron 6 (point mutation or deletion) led to the complete excision of exon 6. The second mutation [240+1G>T] in patient 3 has been described before (9Tiranti V. Jaksch M. Hofmann S. Galimberti C. Hoertnagel K. Lulli L. Freisinger P. Bindoff L. Gerbitz K.D. Comi G.P. Uziel G. Zeviani M. Meitinger T. Ann. Neurol. 1999; 46: 161-166Crossref PubMed Scopus (110) Google Scholar), but its consequence on the RNA sequence was unknown. RT-PCR with the forward primer used to amplify exons 4 to 9 could not detect this mutation, because the mutation was within the primer 4 region. Thus, we used two new primers (For261 and Rev558) that annealed on either side of intron 3. The PCR product (460 bp) obtained with the new primers was 80 bp longer than in the control (380 bp) (Fig. 3 B), and the additional sequence corresponded with that of intron 3. For patient 5 we performed nested PCR with two other primer pairs that normally give a 520-bp fragment, and we obtained a unique band of ∼450 bp (Fig. 3 C). The sequencing of this RT product revealed that the [516–2_516–1delAG] mutation at the acceptor site of intron 5 led to the complete excision of the 73 bp of exon 6, as in patients 1 and 3. We sequenced the genomic DNA PCR products of patients 4, 6, and 7. We found no mutations in DNAs from patients 6 or 7, but we could detect a homozygous polymorphism in intron 8, [835+25C>T] in the DNA of patient 4. The common mitochondrial DNA mutations (myoclonic epilepsy and ragged red fibers, mitochondrial encephalopathy lactic acidosis stroke-like episodes, neuropathy ataxia retinitis pigmentosa, and deletions) associated with LS were ruled out in all patients by restriction fragment length polymorphisms and Southern blot analysis. To determine whether the Surf1 protein is implicated in the stability of other mitochondrial complexes, we carried out enzymatic assays on the respiratory chain complexes and the pyruvate dehydrogenase complex (PDHC) in patients 1, 2, and 3 (who lack the Surf1 protein). Complex II and PDHC activity (Table II), as well as the activities of complexes I and III (data not shown), were comparable with those of controls. Western blot analysis with an antibody directed against PDHC showed subunit-specific bands of similar size and intensity in samples from patients and controls (data not shown). In this study we found that LScox was associated withSURF1 mutations in four of the seven patients (patients 1, 2, 3, and 5). Their clinical presentations were similar to those previously reported, but the incidence of mutations in our study (57%) was between that found by the studies done by Tiranti et al. (9Tiranti V. Jaksch M. Hofmann S. Galimberti C. Hoertnagel K. Lulli L. Freisinger P. Bindoff L. Gerbitz K.D. Comi G.P. Uziel G. Zeviani M. Meitinger T. Ann. Neurol. 1999; 46: 161-166Crossref PubMed Scopus (110) Google Scholar) (75%) and Sue et al. (10Sue C.M. Karadimas C. Checcarilli N. Tanji K. Papadopoulou L.C. Pallotti F. Guo F.L. Shanske S. Hirano N. De Vivo D.C. Van Coster R. Kaplan P. Bonilla E. Di Mauro S. Ann. Neurol. 2000; 47: 589-595Crossref PubMed Scopus (121) Google Scholar) (25%). These differences can be explained by the biochemical and genetic heterogeneity of LS. Of the 58 cases of suspected LS that we studied, 15 had a deficiency in COX activity, 15 had pyruvate dehydrogenase deficiency, 11 were suspected of having complex I defects, and four had neuropathy ataxia retinitis pigmentosa mutations. However, we can confirm that the four cases of typical Leigh syndrome were associated with severe cytochrome oxidase deficiency and have SURF1 mutations (patients 1, 2, 3, and 5). Patients 4, 6, and 7 were also considered to be typical LS cases based on the stringent inclusion criteria, which include the presence of a progressive neurological disease, elevated levels of cerebrospinal lactic acid, and typical MRI abnormalities involving the basal ganglia and brain stem. However, they only had a partial decrease of COX activity, and patients 6 and 7 had no mutations in the SURF1gene. Patient 4 was homozygous for the [835+25C>T] mutation. Interestingly, we found a partial COX defect in the muscles of her cousin; this cousin had the same symptoms and was heterozygous for the same mutation. This change is probably a polymorphism with no pathological significance. We did not notice any phenotypic differences between the three patients (1, 3, and 5) with splicing-site mutations in the SURF1gene. They had early onset severely delayed growth, optic atrophy, neuropathy, and died very early (between 18 months and 4 years). Residual COX activity was always less than 25% of normal. This can be explained by the nature of the mutations and their effect on the protein; patient 1 had both the [312_321del311_312insAT] in exon 4 (2Zhu Z. Yao J. Johns T. Fu K. De Bie I. Macmillan C. Cuthbert A.P. Newbold R.F. Wang J. Chevrette M. Brown G.K. Brown R.M. Shoubridge E.A. Nat. Genet. 1998; 20: 337-343Crossref PubMed Scopus (531) Google Scholar, 3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar), which leads to a truncated protein (with a stop codon at position 105 in the protein), and a deletion in the first base of intron 6, [588+1delG], which results in the production of an RNA in which the skipping of exon 6 predicts the synthesis of a truncated protein (with a stop codon at position 183). Likewise, patient 3 had two splicing mutations, a mutation in the first base of intron 3, [240+1G>T], which results in an mRNA that contains the entire intron 3, with a stop codon after amino acid 89. The second mutation is located in the first base of intron 6; this mutation [588+1G>A] has the same result on the RNA and on the protein as the [588+1delG] mutation described for patient 1. The amplification of only one abnormal band, corresponding to an mRNA retaining intron 3 (Fig.3 B), may be because of the extreme instability of the abnormal RNA that lacks exon 6. Indeed, we obtained a very faint band corresponding to this allele when the first primer pair was used for RT-PCR analysis (Fig. 3 A).Table IIISummary of the clinical features and sequence variations of the SURF1 gene in all patients studiedPatientsOnset (mo)EvolutionClinical featuresMRIMutation or polymorphismProtein19Died 4 yrTypical LS+[312_321del311_312insAT] + [588+1delG][P104fsX105] + [V172fsX183]236Alive 12 yrTypical LS+[312_321del311_312insAT] + [737T>C][P104fsX105] + [I246T]312Died 3 yrTypical LS+[240+1G>T] + [588+1G>A][Q80fsX90] + [V172fsX183]44Alive 15 moTypical LS; familial case, consanguinity+[835+25C>T] + [835+25C>T]5Died 18 moTypical LS consanguinity+[516–2_516–1delAG] + [516–2_516–1delAG][V172fsX183] + [V172fsX183]The nomenclature was according to Péquignot et al.(13Teraoka M. Yokoyama Y. Ninomiya S. Seino Y. Hum. Genet. 1999; 105: 560-563Crossref PubMed Scopus (28) Google Scholar). Open table in a new tab The nomenclature was according to Péquignot et al.(13Teraoka M. Yokoyama Y. Ninomiya S. Seino Y. Hum. Genet. 1999; 105: 560-563Crossref PubMed Scopus (28) Google Scholar). As patient 5 was homozygous for the [516–2_516–1delAG] mutation in intron 5, he had only one species of RNA in which exon 6 was excised, giving a truncated protein with a stop codon at position 183. Three of the six splicing-site mutations have never been described before, two of them are in intron 6 of patients 1 and 3, and the third is the homozygous mutation in intron 5 of patient 5. All of these mutations lead to the excision of exon 6 in mRNA. Paradoxically although the first base of the 5′ splice site is mutated in both the splicing-site mutations in patient 3, the consequences seem to be different. One leads to the retention of the mutated intron 3, whereas the other leads to the excision of the preceding exon, exon 6. The most common effect of a 5′ splice-site mutation is the excision of the preceding exon as observed in the latter case. However, inclusion of the mutant intron is rare. We can explain the retention of intron 3, because intron 3 is generally the last intron to be excised. As a result, the spliceosome machinery does not find any adjacent normal 5′ splicing site, and no splicing occurs (11Lewin B. Gene VI. Oxford University Press, Oxford1997: 889-920Google Scholar). Patient 2, with no splicing-site mutation, had a different phenotype to the other patients (patients 1, 3, and 5). Even though she had typical features of Leigh symptom, she was still alive at 14 years of age. This is probably because of the fact that she had a less severe COX deficiency. We found about 40% residual COX activity in both muscle and lymphoblastoid mitochondria. Patient 2 had the [312_321del311_312insAT] mutation, which results in a truncated protein, and also carried the missense [737T>C] mutation, which transforms Ile246 (ATT) to Thr (ACT). The protein is probably abnormal and too unstable to be detected by Western blot. It is an interesting case, because it is the first described in the literature with a phenotype of a late Leigh syndrome associated with two SURF1 mutations. Our results suggest that respiratory chain complexes (other than complex IV) and PDHC, are normally assembled in patients in which the Surf1 protein is either lacking or abnormal. The Surf1 protein is currently only known to be involved in complex IV assembly. Patients 4, 6, and 7 had all the clinical features of LScox, but no mutation in the SURF1 gene was found. This suggests that although most cases of LScox can be explained by homozygous or compound heterozygous mutations in theSURF1 gene, mutations in other genes may lead to LScox. In this paper, we revealed new splicing-site mutations that are well correlated with the severity of the illness and the dramatic decrease in COX activity. Further studies are necessary to characterize the COX deficiency affecting patients 4, 6, and 7. However, we have confirmed that SURF1 mutations are responsible for Leigh syndrome associated with severe COX deficiency (12Péquignot, M. O., Dey, R., Zeviani, M., Tiranti, V., Godinot, C., Poyau, A., Sue, C., Di Mauro, S., Abitbol, M., and Marsac, C. (2001) Hum. Mutat., in press.Google Scholar) and found a new phenotype of late Leigh syndrome associated with SURF1 mutations never described previously (2Zhu Z. Yao J. Johns T. Fu K. De Bie I. Macmillan C. Cuthbert A.P. Newbold R.F. Wang J. Chevrette M. Brown G.K. Brown R.M. Shoubridge E.A. Nat. Genet. 1998; 20: 337-343Crossref PubMed Scopus (531) Google Scholar, 3Tiranti V. Hoertnagel K. Carrozzo R. Galimberti C. Munaro M. Granatiero M. Zelante L. Gasparini P. Marzella R. Rocchi M. Bayona-Bafaluy M.P. Enriquez J.A. Uziel G. Bertini E. Dionisi-Vici C. Franco B. Meitinger T. Zeviani M. Am. J. Hum. Genet. 1998; 63: 1609-1621Abstract Full Text Full Text PDF PubMed Scopus (446) Google Scholar, 8Poyau A. Buchet A. Bouzidi M.F. Zabot M.T. Echenne B. Yao J. Shoubridge E.A. Godinot C. Hum. Genet. 2000; 106: 194-205Crossref PubMed Scopus (58) Google Scholar, 13Teraoka M. Yokoyama Y. Ninomiya S. Seino Y. Hum. Genet. 1999; 105: 560-563Crossref PubMed Scopus (28) Google Scholar). We are grateful to Dr. G. Ponsot for helpful collaboration and C. Galimberti for technical assistance. We thank Association Retina France and UniversitéRené-Descartes." @default.
• W2128480323 created "2016-06-24" @default.
• W2128480323 creator A5002222771 @default.
• W2128480323 creator A5003756579 @default.
• W2128480323 creator A5013263453 @default.
• W2128480323 creator A5026877040 @default.
• W2128480323 creator A5030685854 @default.
• W2128480323 creator A5030884543 @default.
• W2128480323 creator A5031960202 @default.
• W2128480323 creator A5048857899 @default.
• W2128480323 creator A5060332132 @default.
• W2128480323 creator A5071136848 @default.
• W2128480323 creator A5075442408 @default.
• W2128480323 creator A5081714382 @default.
• W2128480323 date "2001-01-01" @default.
• W2128480323 modified "2023-10-12" @default.
• W2128480323 title "New Splicing-site Mutations in the SURF1Gene in Leigh Syndrome Patients" @default.
• W2128480323 cites W1481324524 @default.
• W2128480323 cites W1569716332 @default.
• W2128480323 cites W1874634989 @default.
• W2128480323 cites W2006159932 @default.
• W2128480323 cites W2022064008 @default.
• W2128480323 cites W2033463352 @default.
• W2128480323 cites W2047941202 @default.
• W2128480323 cites W2139366003 @default.
• W2128480323 cites W2149901817 @default.
• W2128480323 cites W2152403513 @default.
• W2128480323 doi "https://doi.org/10.1074/jbc.m100388200" @default.
• W2128480323 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11279059" @default.
• W2128480323 hasPublicationYear "2001" @default.
• W2128480323 type Work @default.
• W2128480323 sameAs 2128480323 @default.
• W2128480323 citedByCount "25" @default.
• W2128480323 countsByYear W21284803232012 @default.
• W2128480323 countsByYear W21284803232018 @default.
• W2128480323 crossrefType "journal-article" @default.
• W2128480323 hasAuthorship W2128480323A5002222771 @default.
• W2128480323 hasAuthorship W2128480323A5003756579 @default.
• W2128480323 hasAuthorship W2128480323A5013263453 @default.
• W2128480323 hasAuthorship W2128480323A5026877040 @default.
• W2128480323 hasAuthorship W2128480323A5030685854 @default.
• W2128480323 hasAuthorship W2128480323A5030884543 @default.
• W2128480323 hasAuthorship W2128480323A5031960202 @default.
• W2128480323 hasAuthorship W2128480323A5048857899 @default.
• W2128480323 hasAuthorship W2128480323A5060332132 @default.
• W2128480323 hasAuthorship W2128480323A5071136848 @default.
• W2128480323 hasAuthorship W2128480323A5075442408 @default.
• W2128480323 hasAuthorship W2128480323A5081714382 @default.
• W2128480323 hasConcept C104317684 @default.
• W2128480323 hasConcept C2778461778 @default.
• W2128480323 hasConcept C501734568 @default.
• W2128480323 hasConcept C54355233 @default.
• W2128480323 hasConcept C54458228 @default.
• W2128480323 hasConcept C67705224 @default.
• W2128480323 hasConcept C71924100 @default.
• W2128480323 hasConcept C86803240 @default.
• W2128480323 hasConceptScore W2128480323C104317684 @default.
• W2128480323 hasConceptScore W2128480323C2778461778 @default.
• W2128480323 hasConceptScore W2128480323C501734568 @default.
• W2128480323 hasConceptScore W2128480323C54355233 @default.
• W2128480323 hasConceptScore W2128480323C54458228 @default.
• W2128480323 hasConceptScore W2128480323C67705224 @default.
• W2128480323 hasConceptScore W2128480323C71924100 @default.
• W2128480323 hasConceptScore W2128480323C86803240 @default.
• W2128480323 hasIssue "18" @default.
• W2128480323 hasLocation W21284803231 @default.
• W2128480323 hasOpenAccess W2128480323 @default.
• W2128480323 hasPrimaryLocation W21284803231 @default.
• W2128480323 hasRelatedWork W1641042124 @default.
• W2128480323 hasRelatedWork W1990804418 @default.
• W2128480323 hasRelatedWork W1993764875 @default.
• W2128480323 hasRelatedWork W2000789495 @default.
• W2128480323 hasRelatedWork W2013243191 @default.
• W2128480323 hasRelatedWork W2028961943 @default.
• W2128480323 hasRelatedWork W2082860237 @default.
• W2128480323 hasRelatedWork W2117258802 @default.
• W2128480323 hasRelatedWork W2130076355 @default.
• W2128480323 hasRelatedWork W2151865869 @default.
• W2128480323 hasVolume "276" @default.
• W2128480323 isParatext "false" @default.
• W2128480323 isRetracted "false" @default.
• W2128480323 magId "2128480323" @default.
• W2128480323 workType "article" @default.